Drugmakers are outsourcing a greater proportion of Phase II trial budgets and patient recruitment is still the most costly aspect of conducting such studies according to new research.
Sartorius Stedim Biotech (SSB) has revised its full year guidance after its range of single-use products drove revenue gains in the first half of 2011.
ShangPharma said it saw revenue climb on higher customer spending in the fourth quarter, but that margins slid due to currency effects and higher share-based compensation.
Wuxi PharmaTech finished the fourth quarter and the full year 2010 on a high driven by growth across all business units and the payoff from former suitor Charles River Laboratories (CRL).
Nearly half of healthcare supply chain executives are planning to expand into emerging markets in the next 18 months, according to a UPS survey, but are concerned about the process.
Patheon has posted a 12 per cent growth in operating profit in the second quarter and said there is “strong evidence” the business environment is improving.
Kendle International posted a 22 per cent drop in net income to $5m, after a computer error led to problems with a clinical trial carried out for one of its customers.
Gerresheimer posted positive results for 2008, with operating income growing by over 13 per cent, but has acknowledged it will not be able to maintain this momentum in 2009.
Pfizer is likely to lose its crown as the world’s largest pharmaceutical company and by 2012 will be usurped by GlaxoSmithKline, according to a report from Urch Publishing.
Gerresheimer’s decision to concentrate on the pharmaceutical and life science sectors and sell-off non-core divisions appears to be paying dividends judging by a 14 per cent jump in third quarter operating profit.
Agilent recorded strong third quarter revenue growth for its Bio-Analytical segment, which was tempered by the stagnation of income from its Electronic Measurement division.
Invitrogen’s plans to buy Applied Biosystems (ABI) are on track with US antitrust regulators approving the deal and both firms achieving strong revenue growth.
Affymetrix slumped to an operating loss in the second quarter of 2008, reporting flat revenues and blaming a 30 per cent reduction in sales to the pharmaceutical sector.
With fears of a global recession riding on the back of the credit crisis, many laboratory suppliers have managed to weather the storm and still achieve double digit sales growth in the second quarter of 2008.
Oncology drugs are dominating the clinic, with studies on new
anti-cancer compounds representing the largest percentage of new
clinical trials initiated in 2007.
Pharmaceutical companies are having to radically change their
practices when it comes to tackling emerging markets such as China,
India, Russia and Brazil, according to IMS.
Kendle has continued to perform well in its first quarter of 2008,
reporting record sales and new business gains, although its profit
was clouded by expenses.
Although Japan's pharma market sits in firm second position on the
global stage, the country's foothold is slipping as other more
innovative countries grasp for a greater presence.
Applied Biosystems (ABI) reported slight revenue rises in its third
quarter performance, but long term, the lab firm acknowledged its
instrument arm had been negatively affected by a weakened
pharmaceutical environment.
Quintiles Transnational has heralded the results of an
independently conducted study of clinical investigator sites across
Europe that saw the firm rate the highest overall in terms of
satisfaction.
German packaging giant Gerresheimer reported a positive set of
first quarter results for 2008, largely due to the success of its
plastics division in the expanding medical plastics market.
With active pharmaceutical ingredient sales of $1,460m (€960.8m) in
2007 and a portfolio of more than 250 compounds, Teva
Pharmaceutical Industries is by a long stretch the dominant
supplier in the global API market.
Jubilant Organosys, India's largest custom research and
manufacturing services (CRAMS) provider, has scored new contracts
to the tune of $92m for the year thus far as its business continues
to gather momentum.
Earnings growth from its pharma solutions business helped push
BASF's operating income (EBITDA) from fine chemicals up by 56.5 per
cent to €288m in 2007.
Qiagen announced strong Q4 results and good overall growth for
2007, despite going through significant integration and acquisition
efforts. The firm also gave guidance for a 40 per cent growth
rate in 2008.
Beckman Coulter saw its fourth quarter earnings held back by
the cost of acquiring NexGen Diagnostics, but the
underlying business was strong with a near-11 per cent hike in
revenues.
Another sharp decline in biomedical production saw overall
manufacturing output in Singapore fall for the second month running
in December, prompting fears that the heavily trade-reliant economy
could buckle under a looming US recession.
New research from Frost & Sullivan provides a snapshot of
biopharma spending trends on contract research organisations
(CROs), along with forecasts for industry growth.
Russia's clinical trials industry appears to be making a gradual
recovery from a setback earlier this year when the government
imposed an unexpected ban on biologic exports.
PharmaNet has made a strong comeback during its third quarter after
previously slipping into the red and recorded its highest revenue
to date - $99.8m (€70.0m).
Icon has improved its financial position significantly during its
third quarter, while its smaller US rival Kendle saw its profit
slip again, weighed down by charges from a 2006 acquisition.
Covance is feeling positive after reporting healthy growth in both
business units for the third quarter, with its early phase segment
continuing to have the edge over its late stage unit.
Applied Biosystems (ABI) saw 5 per cent revenue growth during its
first quarter of fiscal 2008 as sister company Celera posted
revenue growth of 57 per cent.
Sigma-Aldrich continued its strong year with both revenues and
pre-tax profits showing strong double-digit growth in the third
quarter predicting it will break the $2bn (€1.4bn) revenue mark
this year.
Scanning probe microscope maker Veeco has seen its third quarter
revenues drop 13 per cent to $97.7m (€68.7m) and plans to make 100
staff redundant as part of a restructuring drive.
As second quarter financial results continue to be released
laboratory suppliers Sigma-Aldrich and Invitrogen have both posted
13 per cent revenue growth.
With second quarter financial results being released thick and
fast, laboratory instrument manufacturers Bruker Biosciences and
Illumina have both seen very strong revenue growth.
